Many patients with locally advanced breast cancer do not undergo recommended postmastectomy radiotherapy
the ONA take:
Patients with breast cancer who undergo a mastectomy should receive subsequent postmastectomy radiation therapy (PMRT), which is found to reduce the risk of breast cancer recurrence and improve survival in patients with locally advanced breast cancer with a pathological stage of N2 or N3.
However, only 65% of these patients are receiving the postsurgical radiation therapy, which is the standard of care. In this study, researchers from Louisiana State University (LSU) Health Sciences Center in Shreveport evaluated compliance with the treatment guidelines using the National Cancer Data Base (NCDB).
They reviewed 56,990 de-identified files from NCDB of women with N2 or N3 cancer to determine factors linked to receipt of PMRT.
Their review revealed that only three factors independently predicted a higher likelihood that patients would receive PMRT: receipt of chemotherapy, readmission to the hospital within the first month after mastectomy, and being alive 30 days after the surgery.
In addition, this study highlighted an important issue regarding implementing new research findings into clinical practice.
On average, the time from when a new intervention is recommended as evidence-based practice to full adoption in the clinical setting is 9 years.
Only 65% of patients with advanced breast cancer are receiving the postsurgical radiation therapy.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|